Matthew Tierney

Low-Dose Overlap Transitions from Methadone to Buprenorphine at a Single Opioid Treatment Program

Sarah Rosenwohl-Mack, Scott Steiger, Leslie W. Suen, Brad Shapiro et autres

us (code pays fourni par la source)

Policy priorities to improve access to advanced practice nursing care for mental health and substance use problems: An American Academy of Nursing manuscript

Matthew Tierney, JoEllen Schimmels, Kathleen R. Delaney, Mercy Ngosa Mumba et autres

Nearly 50% of the U.S. population struggles with a mental health or substance use disorder in their lifetime, yet a substantial number are unable to receive treatment or are undertreated due to significant shortages and disparities in the mental health workforce. These …

us (code pays fourni par la source)

Closing the Opioid Treatment Gap Through Advance Practice Nursing Activation

Matthew Tierney, Elizabeth Herskovits Castillo, Adam Leonard, Emily Huang

INTRODUCTION: Buprenorphine, an effective medication for opioid use disorder (MOUD), reduces opioid-related harms including overdose, but a significant gap exists between MOUD need and treatment, especially for marginalized populations. Historically, low MOUD treatment capacity is rising, driven by advanced practice registered nurses …

us, in (code pays fourni par la source)

Enhancing engagement between legislators and nursing to increase buprenorphine access

Deborah S. Finnell, JoEllen Schimmels, Matthew Tierney

us (code pays fourni par la source)

Influences on advance practice nursing education to prescribe medications for opioid use disorder

Bethany J. Phoenix, Matthew Tierney, Susan A. Chapman, Joanne Spetz

BACKGROUND: Opioid misuse is a major public health concern in the United States. Opioid agonist medications are evidence-based treatments for opioid use disorders (OUD) that can be prescribed by advance practice registered nurses (APRNs) with prescriptive authority and appropriate training. PURPOSE: Article …

us (code pays fourni par la source)

Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach

Katie Fitzgerald Jones, Monica O’Reilly Jacob, Joanne Spetz, Laurie Hailer et autres

INTRODUCTION: Drug overdoses have reached a historic milestone of over 100,000 deaths in a single year, 75,673 related to opioids. The acceleration in opioid-related deaths coupled with stark health inequities demands a close examination of opioid use disorder (OUD) treatment barriers and …

us (code pays fourni par la source)

Eliminating the buprenorphine DEA X waiver is critical to promote health equity

Katie Fitzgerald Jones, Monica O’Reilly-Jacob, Matthew Tierney

us (code pays fourni par la source)

Don’t “Waive” Goodbye to Education for Opioid Use Disorder

Richard Bottner, Jeffrey Bratberg, Marlene Martín, Melissa B. Weimer et autres

Introduction As the United States continues grappling with the COVID-19 pandemic, a long-standing and worsening public health crisis escalates. In 2020, more than 93,000 people in the U.S. died of drug-related overdoses largely due to the synthetic opioid fentanyl—the most ever recorded …

us (code pays fourni par la source)

Transforming Mental Health And Addiction Services

Margarita Alegrı́a, Richard G. Frank, Helena Hansen, Joshua M. Sharfstein et autres

Even with great advances in behavioral health policy in the last decade, the problems of mental illness and addiction persist in the United States-so more needs to be done. In this article, which is part of the National Academy of Medicine's Vital …

us, Afrique du Sud (code pays fourni par la source)

Nursing: Addressing Substance Use in the 21St Century

Deborah S. Finnell, Matthew Tierney, Ann M. Mitchell

Over the past two decades, there has shift from focusing on the most severe end of the substance use continuum to earlier detection of persons who are at risk given the consequences associated with alcohol and other drug use. In 2017, the …

us (code pays fourni par la source)

Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder

Abigail Zavod, Sarah Akerman, Martha M. Snow, Matthew Tierney et autres

BACKGROUND: The United States is experiencing an opioid epidemic. Better approaches to encourage outpatient utilization of Food and Drug Administration–approved medications for the treatment of opioid use disorder, including extended-release naltrexone (XR-NTX), are needed. Withdrawal management before initiation of XR-NTX is challenging …

us (code pays fourni par la source)

Two Different Buprenorphine Treatment Settings With Similar Retention Rates: Implications for Expanding Access to Treatment for Opioid Use Disorder

Matthew Tierney, Katerina Melino, Adebowale Adeniji, Martha Shumway et autres

INTRODUCTION: There is considerable need for effective and accessible treatment for opioid use disorder. AIMS: Our study explored differences in buprenorphine treatment retention and duration, with a focus on selected sociodemographic factors and treatment indicators, in two different settings: an office-based buprenorphine …

us (code pays fourni par la source)